Lumos Pharma, Inc. (LUMO)
Dec 12, 2024 - LUMO was delisted (reason: acquired by Double Point Ventures)
4.340
0.00 (0.00%)
Inactive · Last trade price
on Dec 11, 2024
Lumos Pharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Lumos Pharma stock had an average target of 9.38, with a low estimate of 4.25 and a high estimate of 16.
Analyst Consensus: Buy
* Price targets were last updated on Nov 8, 2024.
Analyst Ratings
The average analyst rating for Lumos Pharma stock from 4 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 1 | 1 | 1 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $4.25 | Hold | Reiterates | $4.25 | -2.07% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $28 → $4.25 | Strong Buy → Hold | Downgrades | $28 → $4.25 | -2.07% | Oct 24, 2024 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades $20 → $4.25 | Strong Buy → Hold | Downgrades | $20 → $4.25 | -2.07% | Oct 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +545.16% | Sep 27, 2024 |
| EF Hutton | EF Hutton | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +268.66% | Sep 24, 2024 |
Financial Forecast
Revenue This Year
5.83M
from 2.05M
Increased by 184.11%
Revenue Next Year
867.20K
from 5.83M
Decreased by -85.12%
EPS This Year
-3.83
from -4.18
EPS Next Year
-2.20
from -3.83
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.3M | 2.2M | 45.4M | ||
| Avg | 5.8M | 867,204 | 11.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 985.3% | -63.0% | 5,134.3% | ||
| Avg | 184.1% | -85.1% | 1,231.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -3.53 | -1.18 | -0.74 |
| Avg | -3.83 | -2.20 | -1.33 |
| Low | -3.98 | -3.86 | -2.09 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.